GW Pharmaceuticals – Cannabis Health Magazine

GW Pharmaceuticals Receives U.S. FDA Fast Track

by Cannabis Health August 11, 2015

GW Pharmaceuticals plc has received an U.S. Food and Drug Administration (FDA) has granted Fast Track designation for a proprietary intravenous form of cannabidiol (CBD) to treat Neonatal Hypoxic-Ischemic Encephalopathy (NHIE), and a orphan designation for the same product from The European…

Uncategorized

Developing Cannabis-Based Medicines

by Cannabis Health January 7, 2015

This article has been re-posted from the April – May 2003 Cannabis Health Journal. By Matt Elrod In November 1998, a year before the Institute of Medicine [1] rekindled North American interest in cannabinoid research and the development of cannabis-based Pharmaceuticals, the UK House…